Credit Suisse’s XBiotech XBIT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $2.02M | Hold |
248,270
| – | – | ﹤0.01% | 1851 |
|
|
2023
Q4 | $993K | Buy |
248,270
+3,000
| +1% | +$11.9K | ﹤0.01% | 2339 |
|
|
2023
Q3 | $1.01M | Hold |
245,270
| – | – | ﹤0.01% | 2298 |
|
|
2023
Q2 | $1.46M | Hold |
245,270
| – | – | ﹤0.01% | 2133 |
|
|
2023
Q1 | $846K | Hold |
245,270
| – | – | ﹤0.01% | 2435 |
|
|
2022
Q4 | $861K | Sell |
245,270
-18,438
| -7% | -$62.9K | ﹤0.01% | 2446 |
|
|
2022
Q3 | $955K | Buy |
263,708
+37,561
| +17% | +$177K | ﹤0.01% | 2367 |
|
|
2022
Q2 | $1.27M | Buy |
226,147
+70,294
| +45% | +$473K | ﹤0.01% | 2221 |
|
|
2022
Q1 | $1.34M | Sell |
155,853
-123
| -0.1% | -$1.23K | ﹤0.01% | 2343 |
|
|
2021
Q4 | $1.74M | Buy |
155,976
+20,701
| +15% | +$269K | ﹤0.01% | 2895 |
|
|
2021
Q3 | $1.75M | Sell |
135,275
-21,954
| -14% | -$350K | ﹤0.01% | 2914 |
|
|
2021
Q2 | $2.6M | Buy |
157,229
+82,976
| +112% | +$1.41M | ﹤0.01% | 2636 |
|
|
2021
Q1 | $1.27M | Buy |
74,253
+22,609
| +44% | +$422K | ﹤0.01% | 3151 |
|
|
2020
Q4 | $808K | Sell |
51,644
-650
| -1% | -$12K | ﹤0.01% | 3483 |
|
|
2020
Q3 | $998K | Buy |
52,294
+37,467
| +253% | +$647K | ﹤0.01% | 2937 |
|
|
2020
Q2 | $202K | Sell |
14,827
-25,197
| -63% | -$354K | ﹤0.01% | 3737 |
|
|
2020
Q1 | $425K | Buy |
40,024
+26,981
| +207% | +$439K | ﹤0.01% | 3207 |
|
|
2019
Q4 | $244K | Sell |
13,043
-458
| -3% | -$5.9K | ﹤0.01% | 3912 |
|
|
2019
Q3 | $141K | Buy |
13,501
+1,285
| +11% | +$10.5K | ﹤0.01% | 3929 |
|
|
2019
Q2 | $92K | Buy |
+12,216
| New | +$106K | ﹤0.01% | 3957 |
|
|
2019
Q1 | – | Sell |
-10,026
| Closed | -$51K | – | 4169 |
|
|
2018
Q4 | $51K | Sell |
10,026
-13,709
| -58% | -$56.2K | ﹤0.01% | 3802 |
|
|
2018
Q3 | $76K | Sell |
23,735
-24,482
| -51% | -$95.4K | ﹤0.01% | 3727 |
|
|
2018
Q2 | $217K | Sell |
48,217
-6,620
| -12% | -$29.9K | ﹤0.01% | 3740 |
|
|
2018
Q1 | $293K | Sell |
54,837
-237
| -0.4% | -$1.09K | ﹤0.01% | 3581 |
|
|
2017
Q4 | $216K | Sell |
55,074
-21,675
| -28% | -$91.2K | ﹤0.01% | 3728 |
|
|
2017
Q3 | $334K | Buy |
76,749
+45,190
| +143% | +$213K | ﹤0.01% | 3691 |
|
|
2017
Q2 | $149K | Sell |
31,559
-6,213
| -16% | -$59.5K | ﹤0.01% | 3673 |
|
|
2017
Q1 | $623K | Sell |
37,772
-14,162
| -27% | -$185K | ﹤0.01% | 3157 |
|
|
2016
Q4 | $524K | Buy |
51,934
+10,916
| +27% | +$145K | ﹤0.01% | 3418 |
|
|
2016
Q3 | $552K | Buy |
41,018
+22,605
| +123% | +$332K | ﹤0.01% | 3368 |
|
|
2016
Q2 | $385K | Buy |
+18,413
| New | +$266K | ﹤0.01% | 3566 |
|
Other funds holding XBIT
BCM
Credit Suisse's XBIT Position: Q1 2024 in Review
Credit Suisse held its XBiotech (XBIT) position steady in Q1 2024 at 248,270 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1851.
Credit Suisse first reported a position in XBIT in Q2 2016 and has held it in 31 quarters since. The position peaked at $2.6M in Q2 2021. 46 funds tracked by Wall St. Rank hold XBIT as of Q1 2024.
- Credit Suisse held 248,270 shares of XBiotech worth $2.02M as of Q1 2024.
- Credit Suisse left its XBiotech share count unchanged in Q1 2024.
- XBiotech made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1851 holding.
- Credit Suisse first reported a position in XBiotech in Q2 2016 and has held it in 31 quarters since.
- Credit Suisse's XBiotech position peaked at $2.6M in Q2 2021.
- 46 funds tracked by Wall St. Rank held XBiotech as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.